BeOne Medicines AG (ONC)
| Market Cap | 43.06B +24.8% |
| Revenue (ttm) | 6.13B +34.3% |
| Net Income | 655.71M |
| EPS | 5.59 |
| Shares Out | 113.70M |
| PE Ratio | 66.55 |
| Forward PE | 46.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,055 |
| Open | 370.12 |
| Previous Close | 371.98 |
| Day's Range | 369.49 - 379.45 |
| 52-Week Range | 253.95 - 385.22 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 432.16 (+14.12%) |
| Earnings Date | Aug 5, 2026 |
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $432.16, which is an increase of 14.12% from the latest price.
News
BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA
BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIHERA and chemotherapy for the first-line treatment of ...
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
BeOne Medicines renews partnerships to expand access to Brukinsa in leukemia
BeOne Medicines (ONC), together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a global health nonprofit organization, announced the renewal of their partne...
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundatio...
BeOne Medicines (ONC) Q2 2026 Earnings Call Transcript
BRUKINSA revenue surged 31% while management raised full-year guidance by $300 million.
BeOne Medicines price target raised to $370 from $340 at Wolfe Research
Wolfe Research analyst Kalpit Patel raised the firm’s price target on BeOne Medicines (ONC) to $370 from $340 and keeps an Outperform rating on the shares. BeOne’s $300M guidance increase…
BeOne Medicines partners with Revolution Medicines for clinical development
BeOne Medicines (ONC) and Revolution Medicines (RVMD) announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncolog...
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nas...
BeOne Medicines price target raised to $405 from $395 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $405 from $395 and keeps an Overweight rating on the shares. The company reported a beat-and-raise quarter, with…
BeOne Medicines price target raised to $454 from $424 at TD Cowen
TD Cowen analyst Yaton Werber raised the firm’s price target on BeOne Medicines (ONC) to $454 from $424 and keeps a Buy rating on the shares. The firm updated its…
BeOne Medicines price target raised to $418 from $416 at Truist
Truist analyst Gregory Renza raised the firm’s price target on BeOne Medicines (ONC) to $418 from $416 and keeps a Buy rating on the shares. BeiGene delivered a strong Q2…
BeOne Medicines price target raised to $430 from $420 at Guggenheim
Guggenheim raised the firm’s price target on BeOne Medicines (ONC) to $430 from $420 and keeps a Buy rating on the shares following “positive” Q2 results, including a topline beat…
BeOne Medicines price target lowered to $450 from $451 at RBC Capital
RBC Capital lowered the firm’s price target on BeOne Medicines (ONC) to $450 from $451 and keeps an Outperform rating on the shares.
BeOne Medicines price target raised to $466 from $453 at Citi
Citi raised the firm’s price target on BeOne Medicines (ONC) to $466 from $453 and keeps a Buy rating on the shares. The firm views the Q2 report as strong.
BeOne Medicines price target raised to $405 from $396 at Citizens
Citizens raised the firm’s price target on BeOne Medicines (ONC) to $405 from $396 and keeps an Outperform rating on the shares. BeOne reported strong Q2 results, raised guidance, and…
BeOne Medicines price target raised to $407 from $403 at Barclays
Barclays raised the firm’s price target on BeOne Medicines (ONC) to $407 from $403 and keeps an Overweight rating on the shares. The company reported a “beat and raise” Q2…
BeOne Medicines Q2 Earnings Call Highlights
BeOne Medicines NASDAQ: ONC reported second-quarter revenue of $1.7 billion, up 30% from a year earlier, and GAAP earnings per ADS of $2.05, up 144%, as sales of its BTK inhibitor BRUKINSA continued t...
BeOne Medicines AG Earnings Call Transcript: Q2 2026
Q2 2026 saw 30% revenue growth and a 144% increase in GAAP EPS, driven by BRUKINSA's strong global performance and robust new patient starts. The company raised its 2026 revenue and operating income guidance, advanced multiple pipeline assets, and expanded manufacturing capacity.
BeOne Medicines AG Earnings release: Q2 2026
BeOne Medicines AG released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
BeOne Medicines AG Quarterly report: Q2 2026
BeOne Medicines AG has published its Q2 2026 quarterly earnings report on August 5, 2026.
BeOne Medicines AG Slides: Q2 2026
BeOne Medicines AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Is BeOne Medicines Ltd (ONC) Undervalued After Q2 Earnings Beat? GAAP EPS Hits $2. ...
Is BeOne Medicines Ltd (ONC) Undervalued After Q2 Earnings Beat? GAAP EPS Hits $2.05 on Revenue of $1.7 Billion, GF Score: 77/100
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. announced financial results and corporate updates from the second quarter of 2026.
Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's poten...
BeOne Medicines Expands U.S. Manufacturing With $1 Billion Investment
(RTTNews) - BeOne Medicines Ltd. (ONC) announced a $300 million expansion of its flagship manufacturing and R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey, bringing its tot...